Glycemic Dysregulations Are Associated With Worsening Cognitive Function in Older Participants at High Risk of Cardiovascular Disease: Two-Year Follow-up in the PREDIMED-Plus Study
No Thumbnail Available
Identifiers
Date
2021-10-29
Authors
Gomez-Martinez, Carlos
Babio, Nancy
Julvez, Jordi
Becerra-Tomas, Nerea
Martinez-Gonzalez, Miguel A.
Corella, Dolores
Castaner, Olga
Romaguera, Dora
Vioque, Jesus
Alonso-Gomez, Angel M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers media sa
Abstract
IntroductionType 2 diabetes has been linked to greater cognitive decline, but other glycemic parameters such as prediabetes, diabetes control and treatment, and HOMA-IR and HbA(1c) diabetes-related biomarkers have shown inconsistent results. Furthermore, there is limited research assessing these relationships in short-term studies. Thus, we aimed to examine 2-year associations between baseline diabetes/glycemic status and changes in cognitive function in older participants at high risk of cardiovascular disease. MethodsWe conducted a 2-year prospective cohort study (n=6,874) within the framework of the PREDIMED-Plus study. The participants (with overweight/obesity and metabolic syndrome; mean age 64.9 years; 48.5% women) completed a battery of 8 cognitive tests, and a global cognitive function Z-score (GCF) was estimated. At baseline, participants were categorized by diabetes status (no-diabetes, prediabetes, and = 5-year diabetes duration), and also by diabetes control. Furthermore, insulin resistance (HOMA-IR) and glycated hemoglobin (HbA(1c)) levels were measured, and antidiabetic medications were recorded. Linear and logistic regression models, adjusted by potential confounders, were fitted to assess associations between glycemic status and changes in cognitive function. ResultsPrediabetes status was unrelated to cognitive decline. However, compared to participants without diabetes, those with >= 5-year diabetes duration had greater reductions in GCF (beta=-0.11 (95%CI -0.16;-0.06)], as well as in processing speed and executive function measurements. Inverse associations were observed between baseline HOMA-IR and changes in GCF [beta=-0.0094 (95%CI -0.0164;-0.0023)], but also between HbA(1c) levels and changes in GCF [beta=-0.0085 (95%CI -0.0115, -0.0055)], the Mini-Mental State Examination, and other executive function tests. Poor diabetes control was inversely associated with phonologic fluency. The use of insulin treatment was inversely related to cognitive function as measured by the GCF [beta=-0.31 (95%CI -0.44, -0.18)], and other cognitive tests.= 5-year diabetes duration had greater reductions in GCF (beta=-0.11 (95%CI -0.16;-0.06)], as well as in processing speed and executive function measurements. Inverse associations were observed between baseline HOMA-IR and changes in GCF [beta=-0.0094 (95%CI -0.0164;-0.0023)], but also between HbA(1c) levels and changes in GCF [beta=-0.0085 (95%CI -0.0115, -0.0055)], the Mini-Mental State Examination, and other executive function tests. Poor diabetes control was inversely associated with phonologic fluency. The use of insulin treatment was inversely related to cognitive function as measured by the GCF [beta=-0.31 (95%CI -0.44, -0.18)], and other cognitive tests. ConclusionsInsulin resistance, diabetes status, longer diabetes duration, poor glycemic control, and insulin treatment were associated with worsening cognitive function changes in the short term in a population at high cardiovascular risk.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
cognitive function, diabetes duration, glycated (glycosylated) hemoglobin, insulin resistance, type 2 diabetes, prediabetes, Physical-activity questionnaire, Hypoglycemic episodes, Insulin-resistance, Diabetes-mellitus, Glucose, Decline, Dementia, Validation, Criteria, Midlife
Citation
Collections
SAS - Hospital Universitario Reina Sofía
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
Instituto de Investigación Biosanitaria de Granada (ibsGRANADA)
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - D.S.A.P. Sevilla
Load more Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
Instituto de Investigación Biosanitaria de Granada (ibsGRANADA)
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - D.S.A.P. Sevilla